"This combination seems to be well-tolerated by patients with manageable toxicity, and overall efficacy for the small group seems to be favorable."
Safi Shahda, MD
Advertisement
Articles by Safi Shahda, MD
Advertisement
Latest Updated Articles
Dr. Safi Shahda on a Phase Ib Study Investigating BBI-608 for mPDACPublished: March 10th 2016 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
